Saving Lives by Making Genetic Diagnosis for Cancer Faster and Accessible

OACP IE LTD

[13485 CERTIFIED] | [CE-IVDR COMPLIANT] | [MISA KSA LICENSED]

DNA Tests Are Crucial in Cancer Diagnosis — But Plagued by a Dual Crisis

The Time Barrier

3+ Days
Testing Time

The Talent Gap

Critical Shortage Of Pathologist

Workflow Inefficiencies have a Massive Impact

Increased Mortality Risk

+10%

Death Risk

Per month of treatment delay

Preventable Deaths

126K

Deaths/Year

Attributable to diagnostic delays (est.)

Excess Healthcare Costs

$20B

Extra Costs

In avoidable annual healthcare spending

Current DNA Testing Workflow Bottleneck



Resected Tumour

Sample Prep

DNA Hybridization
12-18 hours

Analysis & Report

The Solution: Two Engines. One Integrated Platform.



ENGINE 1: Rapid Hybridization

Accelerated Chemistry

ENGINE 2: Improved Quality

Digital Pathology AI

How It Works: Zero-Friction Operational Integration

Engine 1: Accelerated Chemistry

Prepare Sample

Add OaCP Buffer

Run Hybridisation

No new equipment,
No protocol redesign,
ZERO switching costs.

Engine 2: Digital Pathology AI

Capture Slide Image

Upload to AICP

Instant AI Inference

Detects hyper/Low-digestion, paraffin artifacts, and confirms neoplastic target cellularity prior to scoring.

Accelerating the Diagnostic Workflow: From 3 Days to 2 Hours With Our Reagents



Resected Tumour

Sample Prep

DNA Hybridization
40 minutes

Analysis & Report

Improving the Reliability and the Quality of Results With Our AI Tool



Resected Tumour

Sample Prep

DNA Hybridization
40 minutes

Analysis & Report

Performance Metrics

2hr

Total Test Time

50%

Cost Savings

98%+

Sensitivity

+56.4%

Margin Uplift

ZERO

Hardware Mods

Proprietary and Certified Technology

Reagents Patent Coverage

The EU

The USA

China

India

AICP Development Roadmap

1 — Q3 2026 — In House model Development

2 — Q1 2027 — AI model implementation and Tuning
With the support of the University of Michigan

UNIVERSITY OF MICHIGAN

MICHIGAN ENGINEERING
CENTER FOR ENTREPRENEURSHIP
UNIVERSITY OF MICHIGAN

3 — Q4 2027 — AI CP Release

$40B Market Opportunity

Hospital Market: EU + USA

Country	No. of Hospitals
Germany	1,800
France	1,200
Italy	800
Spain	730
Poland	600
Portugal	200
Denmark	50
Other EU	3,620
The USA	6,000

Market Segmentation



OaCP Competitive Advantages: Faster – Better – Cost-Effective

Metric	OaCP IE Ltd	Abbott	Agilent	Cytocell
Time to Diagnosis	**2 hours**	1 working day	1+ working day	1+ working day
Overall Test Cost Reduction	**Up to 50%**	None	None	None
No Switch Costs	**✓ Yes**	✗ No	✗ No	✗ No

B2B Sales Model: Global Distribution Network

Direct Customers

Hospitals, Clinical Laboratories, and Independent Distributors

cliniSciences Group

Gentaur

funakoshi
FRONTIERS IN LIFE SCIENCE

Industry Partners

Roche

EVIDENT
OLYMPUS

ikonisys
FINDING THE CELLS THAT MATTER

Market Footprint: >$1M Achieved in EU & Japan



- **The EU**

Roche Gentaur CliniSciences Group

- **The USA**

Roche Gentaur

- **Japan**

funakoshi FRONTIERS IN LIFE SCIENCE

- **KSA**

منشآت monsha'at الهيئة العامة للمنشآت الصغيرة والمتوسطة Small & Medium Enterprises General Authority

ابدأ EBDA

ALNADA MEDICAL شركة الندى الطبية

Team: 100+ Years of Combined Experience

Enrico Di Oto
CEO

BS, MD, PhD,
18 years clinical experience.

Andrea Faviere
CBDO

MBA, 10+ years driving commercial success.

Simone Di Giacomo, CTO

BS, PhD 15+ year in molecular biology.

Nidhal Louhichi
AI Lead

Biomedical Engineer
Digital Health – AI expert.

Feliziano Balladori

35+ years institutional sales.

Matteo Stefanini

PhD in AI.

De-Risked for Explosive Growth

>$1M Revenue Achieved in the EU and Japan

EVIDENT
OLYMPUS
Roche
ikonisys
FINDING THE CELLS THAT MATTER

Partnership with Market Leader

EU-IVDR
NEUTRAL VERITAS TRANSPARENT

IVDR Certified & Compliant
ISO 13485 Certified



Patented Reagents

ROGEL CANCER CENTER
UNIVERSITY OF MICHIGAN HEALTH
UNIVERSITY OF MICHIGAN

Partnership with a Leading University in the USA

3 GOOD HEALTH AND WELL-BEING

VISION رؤية 2030
المملكة العربية السعودية
KINGDOM OF SAUDI ARABIA

Aligned with SDG and Vision 2030 Program

OACP Diagnostics
KSA RN: 24926253927

Roadmap to Leadership & Financial Growth — Next 16 Months

Global Expansion

Deepen Current partnership
USA Market Entry
FDA 510k

AI Tool Launch

Expected for Q1 2027

Saudi Market Entry (Phase 1)

Al-Borg Labs / KAUST / KFSHRC partnership

SFDA & Product distribution

SUPPORTED BY

Bio4Dreams

UNIVERSITY OF MICHIGAN

MICHIGAN ENGINEERING
CENTER FOR ENTREPRENEURSHIP
UNIVERSITY OF MICHIGAN

وزارة الاستثمار
Ministry of Investment

منشآت
monsha'at
الهيئة العامة للمنشآت الصغيرة والمتوسطة
Small & Medium Enterprises General Authority

ابدأ
EBDA

The Ask: $2.7M

45%

Human Capital

30%

Commercial & IP

25%

R&D, FDA & Roche



OaCP Revenues Gap Analisys



Year	Revenues With Current funds	Revenues with Investment	The Gap
2027 (Y1)	USD 0,5 M	USD 0,8 M	+60% (Early US pilots)
2028 (Y2)	USD 1,2 M	USD 2,9 M	+125% (Network Labs USA)
2029 (Y3)	USD 3,0 M	USD 7,4 M	+130% (Scale-up nazionale USA)
2030 (Y4)	USD 5,5 M	USD 10,0 M	M&A Target Range
2031 (Y5)	USD 9,0 M	USD 20,8 M	Exit Strategy Peak

OACP IE LTD

Less Time for Diagnosis
More Time for Life

CEO@OaCP.IT | WWW.OaCPDIAGNOSTICS.COM | @OaCPIELTD

Three Adoption Paths. One Flexible Architecture.

Designed to integrate into any existing lab environment — Roche, Leica, Agilent — without disruption.

OPTION A

Rapid-ISH Chemistry

Reduces test turnaround from **3 days to 2 hours**. 50% cost savings. ISO 13485 certified. Compatible with any manual or automated platform.

Sample Prep → OaCP Rapid Buffer (40-min Hybridisation) → Pathologist Review

OPTION B

AICP Digital Co-Pilot

Automated QC for any pathology lab or OEM microscope provider. Eliminates protocol errors, hyper-digestion, and diagnostic variability.

Slide Imaging → JPG Upload → AICP Analysis → Staining/Protocol Report

OPTION A + B

Full Integrated Stack

Same-day diagnosis with guaranteed protocol standardisation. 2-Hour wet-lab processing + 30-second AI QC. Highest clinical margins at **+56.4%**.

Maximum synergy. Maximum clinical value.

HARDWARE-AGNOSTIC | INDEPENDENT COMMERCIAL STREAM | ISO 13485 CERTIFIED

Three Stakeholders. Three Transformative Benefits.

24/7 EXPERT COPILOT

For Pathology Labs & Technicians

Instant QC feedback detects staining failures, hyper-digestion, and paraffin residue in seconds. Exact corrective parameters provided in real time — empowering junior technicians to achieve senior pathologist accuracy.

COST & RISK REDUCTION

For Hospitals & Health Systems

Eliminates thousands in wasted reagents from repeat testing. Compresses patient turnaround to enable same-day treatment decisions. Ensures identical QC metrics across all satellite network laboratories.

LIFE-SAVING ACCURACY

For Cancer Patients

Eliminates inconclusive FISH results that delay treatment.
Guarantees accurate targeted therapy assignment through standardised diagnostic signals.

Validated on **30,000+ clinical cases**, developed with support of the University of Michigan.

The Ask

A single, structured raise. Four concurrent workstreams. One clear trajectory to Series A.

$2.7M Pre-Series A

18–20 month runway across all four workstreams executing simultaneously.

18–20 Month Runway

Designed to reach FDA clearance, Roche adapter launch, and KSA contract execution before Series A.

Series A-Ready Milestones

US clearance, recurring hospital contracts, and IP ownership create a compelling, de-risked Series A narrative.

Backed by ISO 13485, MISA KSA Licence, University of Michigan endorsement, and a €200K bridge tranche led by Bio4Dreams SPA — this round deploys into validated, de-risked commercial infrastructure.